Nusajaya, Tuesday, 5th May – Kotra Pharma (M) Sdn. Bhd. (Kotra Pharma), the wholly-owned subsidiary of Kotra Industries Bhd., was once again honoured as the Pharmaceutical Company of the Year – Generic Drug Category 2014, by Frost & Sullivan a US based consulting company.
This award for Pharmaceutical Company of the Year – Generic Drug Category was first conferred on Kotra Pharma in 2011, in recognition of its stewardship in customer value and innovation.
“It was an honour and a pleasant surprise to once again receive this award from Frost & Sullivan. To us at Kotra Pharma, it signified yet another positive milestone in our journey to become the centre of excellence for the pharmaceutical industry. It is akin to a nod of recognition that we are on the correct path and that our investment of time, efforts and finances has all been worthwhile in developing and growing our company” said Cheah Ming Loong, General Manager, Ethical Division Kotra Pharma.
Kotra Pharma is a multimillion dollar manufacturing company headquartered in Malaysia, focusing on the research and development of prescription drugs and healthcare supplements.
According to Jonathan Leong, the Research Analyst for Frost and Sullivan, “Kotra Pharma has maintained a strong position in the domestic market through its flagship prescription brands, Axcel and Vaxcel, despite the increasing competition. The company has made significant investments into state-of-the-art research and manufacturing facilities and is expected to expand its geographic presence in the near term. We believe that Kotra Pharma is well-equipped to push its products to the forefront of quality and value.”
To date, Kotra Pharma has a strong global presence in 32 countries worldwide and has invested over USD50million in a new state-of-the-art manufacturing and research facility, which constitutes the largest single-investment on a single location in the history of the Malaysian pharmaceutical industry to date.
As a trail-blazer in the Malaysian pharmaceutical industry, Kotra Pharma through its 30 years has continuously evolved and grown into an internationally recognised brand, receiving acknowledgements internationally and locally. In 2012, Kotra Pharma was acknowledged by the National Pharmaceutical Control Bureau, Ministry of Health Malaysia, through its Industry Excellence Award, for its track record in Good Manufacturing Practices (GMP) and by Reader’s Digest Trusted Brand Gold Award for its health supplement range.
“In this competitive market, we are grateful to be where we are today. We are still very much a young company and accept that we still have a long way ahead of us if we are to achieve our mission to be the centre of excellence for the pharmaceutical industry. We look forward to this journey and continuously challenge ourselves to further expand our annals of achievements. Having said that, we strongly believe and have the conviction to realise both our mission to be the centre of excellence for the pharmaceutical industry and our vision of Humanising Health as we believe everyone deserves a healthier tomorrow” concluded Cheah Ming Loong.
About Kotra Pharma (M) Sdn. Bhd.
Kotra Industries Berhad, via its wholly owned subsidiary, Kotra Pharma (M) Sdn Bhd, engages in the development, manufacturing and trade of pharmaceutical and healthcare products in Malaysia and internationally. The company manufactures a wide range of over-the-counter and prescriptive drugs for clients at every stage of life. Kotra Pharma’s prescription medicines are marketed under Axcel and Vaxcel brands that provide a line of paediatric, anti-infecti0076 e and dermatological products in various dosage forms. The over-the-counter products include health and dietary supplements under the Appeton Brand. The company is headquartered in Melaka and marked its 30th anniversary in 2012.
For more information on Kotra Pharma, visit www.jediwealth.com
Corporate Communication Manager
Tel: +603 7494 0788